Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2399MR)

This product GTTS-WQ2399MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2399MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ342MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ2374MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ13059MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ6657MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ14726MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ8258MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ497MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ5429MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW